Infliximab therapy for hepatic and intestinal sarcoidosis

Gastroenterology and Hepatology

Volumn 3, Issue 6, 2007, Pages 447-452

  Te, Helen S ^a   Campbell, Lucas ^b   Chohan, Saima ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BILE ACID; CARBAMAZEPINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIURETIC AGENT; DOCUSATE SODIUM; GABAPENTIN; HYDROXYCHLOROQUINE; INFLIXIMAB; LACTULOSE; LAMOTRIGINE; MACROGOL; MAGNESIUM CITRATE; METHOTREXATE; METHYLCELLULOSE; NADOLOL; PENTOXIFYLLINE; TEGASEROD; THALIDOMIDE;

ABDOMINAL DISEASE; ADULT; ARTICLE; ASCITES; CASE REPORT; CHOLESTASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; GASTROINTESTINAL ENDOSCOPY; HUMAN; HYPERTENSION; LIVER BIOPSY; MALE; MENTAL DEFICIENCY; PSYCHOSIS; SARCOIDOSIS; SEIZURE;

EID: 34347400371     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Hutchinson J. Case of livid papillary psoriasis. In: Illustrations of Clinical Surgery. Vol. 1. London, England: J&A Churchill Ltd; 1877.
2. Cox CE, Davis-Allen A, Judson MA. Sarcoidosis. Med Clin North Am. 2005;89:817-828.
3. Henke CE, Henke G, Elveback LR, et al. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123:840-845.
4. Rybicki BA, Major M, Popovich J Jr., et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.
5. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736-755.
6. Abe S, Yamaguchi E, Makimura S, et al. Association of HLA-DR with sarcoidosis. Correlation with clinical course. Chest. 1987;92:488-490.
7. Berlin M, Fogdell-Hahn A, Olerup O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary satcoidosis. Am J Respir Crit Care Med. 1997;156:1601-1605.
8. Kunikane H, Abe S, Yamaguchi E, et al. Analysis of restriction fragment length polymorphism for the HLA-DR gene in Japanese patients with sarcoidosis. Thorax. 1994;49:573-576.
9. Martinetti M, Tinelli C, Kolek V, et al. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med. 1995;152:557-564.
10. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111-1118.
11. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-1889.
12. Johns CJ, Schonfeld SA, Scott PP, et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann NY Acad Sci. 1986;465:702-712.
13. Mayock RL, Bertrand P, Morrison CE, et al. Manifestations or sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med. 1963;35:67-89.
14. Reynolds HY. Sarcoidosis: impact of other illnesses on the presentation and management of multi-organ disease. Lung. 2002;180:281-299.
15. Siltzbach LE. Sarcoidosis: clinical features and management. Med Clin North Am. 1967;51:483-502.
16. Blich M, Edoute Y. Clinical manifestations of sarcoid liver disease. J Gastroenterol Hepatol. 2004;19:732-737.
17. Hercules HD, Bethlem NM. Value of liver biopsy in sarcoidosis. Arch Pathol Lab Med. 1984;108:831-834.
18. Devaney K, Goodman ZD, Epstein MS, et al. Hepatic sarcoidosis. Clinico-pathologic features in 100 patients. Am J Surg Pathol. 1993;17:1272-1280.
19. Maddrey WC, Johns CJ, Boitnott JK, et al. Sarcoidosis and chronic hepatic disease: a clinical and pathologic study of 20 patients. Medicine (Baltimore). 1970;49:375-395.
20. Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14:73-76.
21. James DG. Life-threatening situations in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1998;15:134-139.
22. Casavilla FA, Gordon R, Wright HI, et al. Clinical course after liver transplantation in patients with sarcoidosis. Ann Intern Med. 1993;118:865-866.
23. Lipson EJ, Fiel MI, Florman SS, et al. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant. 2005;19:487-491.
24. Dumot JA, Adal K, Petras RE, et al. Sarcoidosis presenting as granulomatous colitis. Am J Gastroenterol. 1998;93:1949-1951.
25. Sprague R, Harper P, McClain S, et al. Disseminated gastrointestinal sarcoidosis. Case report and review of the literature. Gastroenterology. 1984;87:421-425.
26. MacRury SM, McQuaker G, Morton R, et al. Sarcoidosis: association with small bowel disease and folate deficiency. J Clin Pathol. 1992;45:823-825.
27. Lindgren A, Engstrom CP, Nilsson O, et al. Protein-losing enteropathy in an unusual form of sarcoidosis. Eur J Gastroenterol Hepatol. 1995;7:1005-1007.
28. Popovic OS, Brkic S, Bojic P, et al. Sarcoidosis and protein losing enteropathy. Gastroenterology. 1980;78:119-125.
29. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135:27-31.
30. Godeau B, Farcet JP, Delchier JC, et al. Protein-losing enteropathy in gastrointestinal sarcoidosis associated with malignant lymphoma. J Clin Gastroenterol. 1992;14:78-80.
31. Beniwal RS, Cummings OW, Cho WK. Symptomatic gastrointestinal sarcoidosis: case report and review of the literature. Dig Dis Sci. 2003;48:174-178.
32. Stampfl DA, Grimm IS, Barbot DJ, et al. Sarcoidosis causing duodenal obstruction. Case report and review of gastrointestinal manifestations. Dig Dis Sci. 1990;35:526-532.
33. Hilzenrat N, Spanier A, Lamoureux E, et al. Colonic obstruction secondary to sarcoidosis: nonsurgical diagnosis and management. Gastroenterology. 1995;108:1556-1559.
34. Aaronson HG, Meir JH, Ulin AW. A case of sarcoidosis of the colon. J Albert Einstein Med Cent (Phila). 1957;6:14-16.
35. Fleming RH, Nuzek M, McFadden DW. Small intestinal sarcoidosis with massive hemorrhage: report of a case. Surgery. 1994;115:127-131.
36. Veitch AM, Badger I. Sarcoidosis presenting as colonic polyposis: report of a case. Dis Colon Rectum. 2004;47:937-939.
37. Yamaguchi E, Itoh A, Hizawa N, et al. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest. 2001;119:753-761.
38. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol. 1993;92:14-18.
39. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156:1586-1592.
40. Armstrong L, Foley NM, Millar AB. Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis. Thorax. 1999;54:524-530.
41. Ziegenhagen MW, Rothe ME, Zissel G, et al. Exaggerated TNF alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:185-190.
42. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43:7-11.
43. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064-1071.
44. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63:318-320.
45. Sweiss NJ, Welsch MJ, Curran JJ, et al. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005;53:788-791.
46. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660-1661.
47. Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNF alpha (infliximab). Eye. 2005;19:841-845.
48. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol. 2004;150:146-149.
49. Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533-536.
50. Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2003;48:290-293.
51. Mandel L, Wolinsky B, Chalom EC. Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case. J Am Dent Assoc. 2005;136:1282-1285.
52. Menon Y, Cucurull E, Reisin E, et al. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004;328:173-175.
53. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol. 2003;2:413-414.
54. Roberts SD, Wilkes DS, Burgett RA, et al. Refractory sarcoidosis responding to infliximab. Chest. 2003;124:2028-2031.
55. Sorrentino D, Avellini C, Zearo E. Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale. Inflamm Bowel Dis. 2004;10:438-440.
56. Thumfart J, Muller D, Rudolph B, et al. Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. Am J Kidney Dis. 2005;45:411-414.
57. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-74.
58. Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs. 2003;17:425-431.
59. Steffen M, Petersen J, Oldigs M, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91:939-949.
60. Di Sabatino A, Ciccocioppo R, Benazzato L, et al. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther. 2004;19:1019-1024.